Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2022-08-11 Earnings Release
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2022, reporting the issuance of a press release announcing financial results for the fiscal quarter ended June 30, 2022. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K itself is a current report, not the full financial report. The document length is 3516 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than containing detailed financial data or analysis. According to the 'Menu vs Meal' rule, this is an announcement of a report (the earnings release) rather than the report itself. Therefore, the correct classification is Earnings Release (ER).
2022-08-11 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an announcement about the FDA planning to reconvene an advisory committee to discuss a New Drug Application, including a press release attached as an exhibit. There are no financial statements or detailed financial data included, and the document is relatively short (3,719 characters). It is primarily an announcement of an event rather than a full financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-07-05 English
SC 13G
Major Shareholding Notification
2022-06-21 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 13, 2022. It announces a regulatory approval event by Health Canada for the company's product ALBRIOZA. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. The length is 3579 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on a significant corporate event (regulatory approval) rather than financial results, management changes, or other categories. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2022-06-13 English
FORM 4 SUBMISSION
Director's Dealing
2022-06-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.